Next generation sequencing (NGS) has revolutionized the analysis of human genetic variations, offering a highly costeffective way to diagnose monogenic diseases (MDs). Because nearly half of the children with chronic liver disorders have a genetic cause and approximately 20% of pediatric liver transplantations are performed in children with MDs, NGS offers the opportunity to significantly improve the diagnostic yield in this field. Among the NGS strategies, the use of targeted gene panels has proven useful to rapidly and reliably confirm a clinical suspicion, whereas the whole exome sequencing (WES) with variants filtering has been adopted to assist the diagnostic workup in unclear clinical scenarios. WES is powerful but challenging because it detects a great number of variants of unknown significance that can be misinterpreted and lead to an incorrect diagnosis. In pediatric hepatology, targeted NGS can be very valuable to discriminate neonatal/infantile cholestatic disorders, disclose genetic causes of acute liver failure, and diagnose the subtype of inborn errors of metabolism presenting with a similar phenotype (such as glycogen storage disorders, mitochondrial cytopathies, or nonalcoholic fatty liver disease). The inclusion of NGS in diagnostic processes will lead to a paradigm shift in medicine, changing our approach to the patient as well as our understanding of factors affecting genotype-phenotype match. In this review, we discuss the opportunities and the challenges offered nowadays by NGS, and we propose a novel algorithm for cholestasis of infancy adopted in our center, including targeted NGS as a pivotal tool for the diagnosis of liver-based MDs.
genetic test aimed at answering a question that arose from a specific clinical suspicion, pointing toward a selected genetic target. (2) This gene-centered approach, although very reliable to detect single mutations, was inefficient and expensive because it often required several attempts to make a diagnosis.
In recent years, the introduction of NGS has accomplished the simultaneous analysis of a large number of genes, up to whole exome sequencing (WES) or even whole genome sequencing (WGS). (3) Nowadays, it is possible to sequence the complete human genome within a few hours at relatively low cost, using widely available technologies that are becoming increasingly powerful and whose limitations are more interpretative than technical. (4) Progress in DNA sequencing and genotyping array technology allow the detection of variants, deletions, and duplications at the genome level. Among these techniques, targeted gene sequencing (TGS) and WES are particularly useful to retrieve point mutations that are causative of monogenic diseases (MDs). (5) There is no doubt that genetic testing may contribute to a prompt identification of patients with a MD. Nevertheless, it is illusory to think that the recognition of a genetic defect can fully characterize the clinical features of a Mendelian condition. (6) Indeed, environmental factors, usually referred to as epigenetic modifiers, deeply affect the phenotypic expression of MDs. (7) In this complex setting, a deeper knowledge of genomic variants represents the main stride toward the understanding of the determinants of genotype-phenotype match in MDs. (8) Besides, the availability of rapid mutation detection in disease-related loci can offer the opportunity to identify unexpected clinical pictures for a certain gene variant.
NGS is a rapidly expanding technology, and its applicability is well ahead of the current clinical use. Because approximately 20% of all pediatric liver transplantations (LTs) are performed in children with MDs affecting the liver, (9) the opportunity to simultaneously investigate a panel of genes may potentially increase the detection rate for an inherited condition. This review aims at describing the value of the NGS as a diagnostic tool in pediatric hepatology and for decision making in the setting of pediatric LT.
Next Generation Sequencing
The Sanger technique has proven enormously successful due to its precision and affordability, but it is unsuitable for large-scale screening projects because it has been designed to sequence only 1 individually amplified DNA molecule at a time. (2, 10) Conversely, massively parallel or "next generation" sequencing has made it possible to generate large amounts of sequence data analyzed simultaneously, thus providing variant information down to single-base resolution in a rapid, cost-effective, and high-throughput fashion on the scale of the whole human genome.
Enrichment techniques by either solid or liquid capture hybridization or amplicon methods allow rapid isolation of the candidate regions of interest (ROIs) ranging from hundreds of kilobases in size to the entire proteincoding sequence of an individual (the "exome"). (11) Briefly, NGS involves 3 fundamental steps: sample preparation, sequencing, and data analysis. (12) Successful sequencing is highly dependent on the efficiency of the enrichment procedure during sample preparation, and it depends also on the type of bases of the ROI.
Following sequencing, data analysis involves further steps, including base calling, read alignment, variant calling, and a process of prediction of causality for the genetic variants identified called "annotation." This analysis may include a search for the presence of the variant in public databases and the degree of evolutionary conservation of the encoded amino acid, and an in silico prediction of whether the variant is pathogenic (due to its potential impact on protein function using computer-based algorithms). (13) (14) (15) NGS Protocols: From Scenario-Specific Panels to WGS
TARGETED GENE SEQUENCING
The use of targeted panels has the advantage to focus on a limited number of suspected diseases, has a better coverage of the genes of interest, and is time-and costsaving when it comes to reporting. (16) Similarly to Sanger sequencing, this technique is suitable as a confirmation of a clinical suspicion based on signs, symptoms, and biochemical tests. In pediatric hepatology, TGS is particularly indicated to characterize genetic cholestatic disorders, most commonly presenting early in life with conjugated hyperbilirubinemia, or to identify different disease subtypes causing a similar metabolic derangement, such as glycogen storage disorders, mitochondrial disorders, and nonalcoholic fatty liver disease. (17) (18) (19) In defined conditions or syndromes, clinical features and biochemical markers can guide the investigation toward a specific pathway or group of genes responsible for a given phenotype. In these cases, a TGS analysis has proven efficient and cost-effective. (20) Table 1 reports a list of common MDs of the liver that can be detected by targeted NGS techniques.
In our institution, we have developed a customized TGS panel that, at the time of writing, comprises the recurrent acute liver failure; ROI, region of interest; SMPD1, sphingomyelin phosphodiesterase 1; SNV, single nucleotide variants; TALDO, transaldolase; TGS, targeted gene sequencing; Tyr, tyrosinemia; VUS, variant of unknown significance; WES, whole exome sequencing; WGS, whole genome sequencing. WHOLE EXOME SEQUENCING Rapid progress in capture designs has allowed all protein-coding regions to be sequenced without a significant increase in costs. For this reason, interest is rapidly shifting toward WES.
The use of WES is recommended to improve the diagnostic yield in cases of an uncertain or compound phenotype, with a likely inheritable background but no clear pointers to the diagnosis.
A tight liaison between the laboratory geneticist and the clinician is necessary to ascertain the correct diagnosis from WES, which involves filtering of gene candidates, on the basis of phenotypic features disclosed by previous clinical investigations, and type of inheritance as judged by analysis of parental DNA. (22) CLINICAL EXOME SEQUENCING In several cases, WES does not point to the genetic diagnosis because most of the generated data includes genes not yet implicated in human disease. In these 
WHOLE GENOME SEQUENCING
WGS is the sequencing of all the genome-coding and noncoding regions-and offers a resolution that is not available with other sequencing methods. (23) WGS has the advantage-over WES and TGS-of identifying 3 categories of variants: structural rearrangements of part of the genome, such as chromosomal translocations or inversions or dosage, otherwise visible only with karyotype or array-CGH; regulatory intronic regions; and GCrich regions, which are less efficiently amplified by polymerase chain reaction and thus are better explored with the most recent polymerase chain reaction-free WGS.
Interpretation of the Results and Reporting
Each test performed by NGS generates thousands to millions of base pairs (bps) of DNA and detects numerous variants, the number depending on the size of the ROIs (Fig. 1 ). All these data must be filtered and interpreted, with the help of storage facilities, bioinformatic technologies, and disease databases.
Classic genetic testing is usually performed to confirm a clinical phenotype linked to a known genetic disease. However, the novel sequencing technology is often applied as a screening method, especially in unusual and clinically undefined cases. Not rarely in these patients does a discrepancy between genetic test and clinical significance often occur. For this reason, it is often helpful to have a hypothesis of the type of inheritance on the basis of family history (autosomal dominant or recessive, sporadic condition, or X-linked transmission), so that the NGS strategy and reporting can be tailored to the specific case.
Among pathogenic variants, those causing a stop codon or a truncating protein can be considered likely to be causative of a disease, whereas variants related to missense mutations (having variable effects on different proteins) are unpredictable as far as posttranscriptional residual function. Aspects supporting the pathogenicity of a variant causing a missense mutation are as follows:
1. The previous report in human genome databases. 2. Minor allele frequency (MAF) in the general population (the higher the frequency, the lower the probability to be causal in rare diseases). (24) 3. Evidence of a causative role in published literature.
FIG. 1.
Total number of variants (SNPs and indels) upon stepwise expansion of analyzed genomic portions, expressed as bps and sequencing strategy (from targeted genes to whole genome). In the bottom part of the figure, the correlation among the platform throughput, the technical accuracy, and the interpretative complexity are shown. Although the technical accuracy decreases, the amount of data and its complexity rise exponentially.
4. Cosegregation with the disease within the same family. 5. De novo variant in a sporadic condition. 6. Biostatistical prediction models.
In our center, after filtering, the remaining variants are classified in accordance to the most recent guidelines. (25) Only variants associated with the patient phenotype that are present in HGMD Professional 2013.4 (Qiagen, Redwood City, CA) and/or ClinVar (26) are included in the final report as "pathogenic mutations." (15) Variants found in genes implicated in the patient phenotype and classified as potentially pathogenic by the American College of Medical Genetics that have not been previously described, or those present in HGMD without any functional validation, are reported as variants of unknown significance (VUS) needing further investigations. (9, 27) Limitations of NGS Pitfalls of the technique can be technical and interpretative. Indeed, the amount of data is not uniformly distributed on the analyzed region. The coverage, defined as the number of aligned reads that include a given nucleotide in the reconstructed sequence, represents the capability to discriminate between sequencing error and true variant. In general, the larger the number of genes, the less accurate the coverage, the bigger the number of variants, the more difficult the interpretation (Fig. 1) . (28) With broader approaches, such as WES, previous experiences have shown incomplete capture of target regions, with 40% of targeted bases and 20% of known disease-causing sites resulting as poorly covered. (29) It is therefore clear that a critical phase in the whole exome or genome studies is the enrichment phase, which requires substantial technical improvements. (30) Beside these technical issues that are increasingly overcome, the interpretative challenges become more relevant, especially with the increase of the number of genes explored. WGS, more expensive and less feasible in daily practice, produces more than 100 Gb of data per single test, thus a major effort is required to perform bioinformatic analysis and to safely store all gathered information. (31) Most of the detected variants have not been definitely linked to a disease (VUS), and therefore, inevitable incidental findings may lead to a diversion from the diagnosis in the absence of adequate interpretation. If a VUS is found in a gene whose implication is highly suspect for a certain clinical picture, further studies might be required to elucidate its role. These studies may consist in looking for the biochemical fingerprint of the suspected disease, in an in silico prediction analysis for the variants found, or in relevant messenger RNA studies in case the variant is supposed to behave as a splice enhancer or silencer.
Finally, although exceedingly effective in identifying single nucleotide variants, substitution, and insertion/ deletion of few nucleotides, NGS is inherently inaccurate for other genomic variations, such as copy number, structural rearrangements (translocation and inversion), or partial rearrangements of a gene. Furthermore, the most commonly adopted NGS strategies are not able to detect triplet expansion or methylation status of a given genomic region.
Burden of Monogenic Liver Diseases in Children
Nearly half of chronic liver disorders presenting in childhood have a genetic cause, and approximately 20% of LTs in children are performed as a consequence of liver-based MDs.
(9) If we exclude biliary atresia (the most frequent indication for pediatric LT) and autoimmune liver disease, most of the remaining conditions causing progressive serious liver disease in childhood are inheritable. It is therefore clear that, in this setting, a powerful instrument to discover pathogenic variants bears a revolutionary power in the clinical management of a child presenting with liver disease. (32) Although most skilled clinicians would regard NGS as a very inelegant diagnostic tool, the opportunity to confirm the diagnosis with a simple peripheral blood sample, while avoiding invasive procedures and complex biochemical tests, is undoubtedly appealing. NGS entails a major shift in the clinical approach to suspected genetic liver disease: from the classical scenario, in which hypotheses rise from clinical and biochemical data and lead to genetic confirmation, to a new one, in which candidate disease-associated variants are filtered and are matched with the clinical picture. A major advantage of the NGS in pediatric hepatology is that it overcomes possible laboratory pitfalls. In fact, in the subclinical/early phase, clinical and biochemical hallmarks may be absent or insufficient to make the diagnosis until a trigger (diet, oxidative stress, infections) produces a consistent (and sometimes irreversible) metabolic derangement. (33) Similarly, at the other end of the spectrum, in a child with end-stage liver disease or with acute decompensation, looking for a specific metabolite pattern can be tricky; in fulminant liver failure, genetic testing may represent the only way to achieve a diagnosis of a metabolic condition. (34) NGS will never replace biochemical and enzymatic tests in the management of MDs, but it may act as a bundle tool able to provide a fast and reliable diagnosis, especially in unclear phenotypic presentations. Reciprocal confirmation between the genetic and biochemical diagnoses is recommended, when feasible. Table 2 reports some clinical hints to the suspicion of MDs in patients presenting with or having an ongoing liver disease.
Usefulness of NGS in Pediatric Hepatology/Liver Transplant Centers

CLINICAL SCENARIO: CHOLESTASIS OF INFANCY
Cholestatic liver disease affects approximately 1/2500 term infants and is most commonly due to biliary atresia (up to 40% of patients). (35) In the past, up to 60% of infants with neonatal cholestasis and a histological pattern of giant cell hepatitis were classified as "idiopathic neonatal hepatitis." This term is now used much less frequently because modern tools allow recognition of specific genetic syndromes; as a consequence, the rate of infants diagnosed with "neonatal idiopathic cholestasis" has dropped to less than 20% of all infants presenting with conjugated jaundice. (36) Conversely, in the early NGS era, a genetic cause is eventually identified in approximately 40% of the cases in which biliary atresia is ruled out; thus, this technique represents a very powerful tool to recognize liver genetic disorders, reducing the percentage of "idiopathic" cases. Genetic causes of cholestasis are depicted in Table 1 .
Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders caused by a disturbance of the bile acid transport through the canalicular membrane, and it accounts for more than 10% of the children with neonatal cholestasis. PFICs are almost uniquely associated with a low gamma-glutamyl transpeptidase (GGT) serum level (only the rare inborn errors of bile acid synthesis/conjugation-having the hallmark of low/normal serum primary bile acids-share this feature), and they are indistinguishable from each other on clinical grounds. (37) (38) (39) (40) (41) The most important value of applying NGS in the field of early onset cholestasis is the opportunity to rapidly identify the defect causing low-GGT PFICs (PFIC1, PFIC2, TJP2-related cholestasis, and the recently discovered Myosin VBassociated cholestasis). (42, 43) Indeed each defect bears the risk of different complications before and after transplantation (such as severe post-LT diarrhea, steatosis, and graft loss in PFIC1, and the risk of hepatocellular carcinoma [HCC] in the native liver or recurrent immune-mediated disease after LT in PFIC2). (44) (45) (46) (47) Thus, genetic characterization is the crossroad for making decisions about possible medical management, surgical bile acid-lowering treatment (eg, biliary diversion), or toward transplantation.
The diagnosis of other MDs presenting with infantile cholestasis may be very difficult without genetic testing. Some examples are given by patients with bile acid conjugation defects (such as familial hypercholanemia due to bile acid-CoA:amino acid N-acyltransferase [BAAT] deficiency) having a defect of amidation of the primary bile acid that requires mass spectrometry or specific liver immunostaining to be revealed. (48) Citrin deficiency (neonatal-onset type II citrullinemia) may present clinically with prolonged jaundice and failure to thrive but with otherwise nonspecific histology and liver tests and with a normal serum amino acid profile. In all these patients, NGS has proven to be a very effective tool to disclose rare types of genetic cholestasis. (49) AS is commonly diagnosed on clinical grounds on the basis of the historical clinical criteria described by Alagille et al. in 1975 . (50) Almost all the genetically confirmed cases in our experience had previously been suspected (data not published). Nevertheless, because of the variable penetrance of this autosomal dominant condition, AS has a wide spectrum of clinical disease expression and severity; for this reason, many such patients not fulfilling the classical clinical criteria remain undiagnosed, unless JAG1 and NOTCH2 disease-causing variations are regularly looked for. (51) Being aware of such conditions before LT is offered is important because it allows the identification and possibly the treatment of coexisting pulmonary artery stenosis or intracranial vascular malformations at risk of potentially devastating complications. (52) Remarkably, 5%-7% of AS patients have a partial or complete deletion of JAG1, which may not be detected by NGS. Thus, when the clinical suspicion is high and NGS is not diagnostic, a more specific test for structural rearrangements should be performed. The multiplex ligation-dependent probe amplification (MLPA) is in some way complementary to NGS in these cases: inexpensive, straightforward, and it uses pairs of probe oligonucleotides designed so that the amplification product depends on the number of target sites present in the sample DNA. This makes the technique highly reliable in detecting copy number variations of DNA regions and single genes or part of them: in a child with the typical AS phenotype seen at our unit in which our TGS was negative, MLPA showed an amplification pattern of hemizygous deletion of the whole JAG1, which confirmed the diagnosis.
In some inborn errors of metabolism causing severe liver disease early after birth, NGS overcomes the problem of securing the diagnosis in patients already started on a substrate-free diet. This is especially the case of galactosemia, in which the marker metabolite rapidly disappears and a lactose challenge is harmful. (53) Lysosomal storage disorders (such as Niemann-Pick Type B and C, Gaucher disease, and lysosomal acid lipase [LAL] deficiency) are hallmarked by splenomegaly and can present with neonatal cholestasis. (54) Although the standard diagnosis is usually made by enzymatic testing, this type of assay is not widely available and needs access to a specialized laboratory, with some time lapse before the diagnosis can be made. NGS may not offer faster results, but it has the advantage of making the diagnosis and defining the genotypic signature of the condition (often corresponding to different predicted outcomes). It can be particularly useful to the pediatric hepatologist as part of a NGS panel for patients presenting early in life with cholestasis. (55) Finally, it is in alpha-1-antitrypsin deficiency (A1ATD) that genetic testing has a limited role. Because the disease can present early in life with clinical and histological features mimicking biliary atresia, it should be ruled out before performing a liver biopsy and a direct cholangiography. A borderline or frankly low serum alpha-1-antitrypsin (A1AT) level is generally a good pointer to the diagnosis. In unclear cases, the A1ATD genetic signature should therefore be obtained either by isoelectrofocusing (giving the detailed A1AT phenotype) or genotyping. (56) At our institution, infants with conjugated hyperbilirubinemia undergo a stepwise evaluation in which a NGS-expanded panel for genetic liver diseases (Bergamo Liver Panel, genes indicated with an asterisk in Table 1 ) acquires a pivotal role to the diagnosis. Figure  2 illustrates this novel approach, which is currently under evaluation in a prospective study. In this algorithm, which should be regarded as a local choice, stool color, liver biopsy pattern, and GGT level are the main crossroads, whereas intraoperative cholangiogram and NGS lead to the conclusive diagnosis. Preliminary results show that-in this pediatric LT setting-the detection rate of genetic causes of infantile cholestasis is above 50% and that NGS is cost-effective when compared with traditional stepwise diagnostic approaches based on clinical and biochemical pointers (data not published).
CLINICAL SCENARIO: ACUTE LIVER FAILURE IN CHILDREN
The cause of acute liver failure (ALF) in children remains indeterminate in approximately half of patients. An underlying MD causing severe metabolic derangements is identified in 10%-28% of children with ALF, (57, 58) largely depending on the diagnostic capabilities of the center. Genetic causes of ALF and possible clinical and biochemical features are depicted in Fig. 3 . The earlier the presentation of ALF, the higher the suspicion for an inherited metabolic disease (IMD) should be maintained. The management of a child with ALF is challenging. Children with ALF are often listed for LT before a diagnosis is achieved. Reaching a timely diagnosis, however, is of great importance in this scenario because IMD may respond to medical treatment, and-converselysome of them represent relative contraindications to LT. (59, 60) The importance of a rapid genetic diagnosis is even greater considering that-during acute decompensation-appropriate biochemical and histological evaluations can be unfeasible or ineffective because of the instability of the patient and the numerous confounders produced by severe organ injury. In this setting, in the near future NGS will probably represent a pillar in the management of ALF, effectively identifying underlying IMDs, provided the turnaround time is fast enough to impact on decision to transplant or not.
The genetic causes of ALF are galactosemia, fructosemia, mitochondrial depletion syndromes (MDSs), tyrosinemia (Tyr) type 1; more rarely congenital glycosylation defect (CDG; especially CDG-1a) and fatty acids oxidation defects, often presenting with a Reyelike picture; in males in the postneonatal period, ornithine transcarbamylase (OTC) deficiency should be considered. In older children, a relatively common cause is Wilson's disease.
Galactosemia and fructosemia can present as cholestatic liver disease during infancy beside ALF. These diseases respond dramatically to the substrate-free diet (galactose and fructose, respectively), but challenging a fragile infant with these sugars to make the definite diagnosis is unadvisable.
Tyr type 1 is easily diagnosed by observing the plasma amino acid profile and urine succinylacetone, and usually genetic testing is performed only as a confirmation.
MDS is mainly related to mutations in genes involved in the respiratory chain, having heterogeneous phenotypes, most commonly characterized by a defect of cellular energy production. As such, they are systemic diseases in which organ transplantation is generally contraindicated. Those presenting with liver involvement are related to nuclear gene products responsible for mitochondrial DNA replication (POLG1), maintenance of deoxyribonucleoside triphosphate pools (DGUOK), and membrane mitochondrial integrity (MPV17). (61, 62) Therefore, mutations in these genes cause mitochondrial DNA depletion, characterized by hepatocerebral forms inherited with an autosomal recessive pattern. In Alpers' syndrome (due to mutations in POLG1), sodium valproate administered because of intractable seizures often triggers acute liver decompensation and death. The histological changes on liver biopsy include fatty degeneration, bile duct proliferation, fibrosis, and lobular collapse, (63) but NGS warrants a rapid confirmation of the diagnosis, which is therefore relevant for the management of these patients.
Undoubtedly, the wide clinical and biochemical heterogeneity of MDSs represents a diagnostic challenge. The complex contribution of nuclear and mitochondrial genes on mitochondrial function and integrity, associated with the occurrence of heteroplasmy (random mixture of mitochondria with normal and mutant DNA in different tissues) makes the clinical phenotype unpredictable. Enzymatic assays on muscle biopsy are time-consuming, whereas a low enzymatic activity on liver biopsy could be secondary. Nevertheless, TGS can be very effective in the suspicion of such defects because these are caused by mutations in very few genes. (64) Remarkably, NGS helps to discriminate cases of acutely ill children in which mitochondrial DNA depletion was secondary to acute liver injury. (19) Genetic information, neurologic status, and ethical considerations should be part of the evaluation of these children.
A complete list of the genes associated with ALF is in Table 1 .
In conclusion, NGS allows the detection of a large number of variants in clusters of genes, and it is becoming a widely available and standardized technique that, combined with biochemical data and phenotype examination, may rapidly lead to the correct diagnosis of all known monogenic liver diseases. NGS will never replace biochemical testing that is central to establish the clinical phenotype, but it represents a great advantage to make the diagnosis in absence of clues or in difficult cases, also offering genotype-phenotype correlation.
Its use may reduce the time to diagnosis, the number of invasive tests or procedures, facilitate decision making, and fill the gap of the laboratory diagnostics in certain situations. With the growing adoption of CES, WES, and WGS in the next years, it will be important to optimize and standardize a diagnostic procedure that combines clinical phenotype, genetic testing, and biochemical tests.
Several challenges remain to be faced with this new instrument, such as the choice of NGS techniques in different clinical scenarios, the selection criteria to test a patient, the filtering strategy in WES and WGS, and how to report negative results or VUS. Nevertheless, it is likely that due to cost-effectiveness, in the future, WGS will replace targeted sequencing, but only selected "virtual" panels of genes, chosen depending on the patient phenotype, will be analyzed; this will offer the possibility to assess the bioinformatically stored data of the entire exome/genome at a later stage.
The inevitable inclusion of NGS in diagnostic algorithms will lead to a new era in medicine, changing our approach to the patient as well as our understanding of the genotype-phenotype match in MDs.
